David Chang
Fortune : 27 368 $ au 30/06/2026
Fortune : 27 368 $ au 30/06/2026
David J.
Chang is currently Chief Medical Officer at Cabaletta Bio, Inc., a position held since 2019.
Formerly, Dr. Chang was Senior Vice President, Head-IA&NS at AstraZeneca Pharmaceuticals LP from 2015 to 2019.
Prior to that, the role of VP & Head-Immuno-Inflammation was held at GSK Plc from 2007 to 2015.
Education includes graduate studies at Emory University, undergraduate studies at Yale University, and a doctorate from New York University School of Medicine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,01 % | 10/04/2026 | 8 800 ( 0,01 % ) | 27 368 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CABALETTA BIO, INC. | Directeur Technique/Scientifique/R&D | 01/06/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Corporate Officer/Principal | 01/05/2019 |
| GSK PLC | Corporate Officer/Principal | 01/06/2015 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Emory University
Emory University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceuticals | Health Technology |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national